Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
NCT03742349 · Novartis Pharmaceuticals · PHASE1 · terminated · last registry update 2025-05-18 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This was a sponsor decision and was not a consequence of any safety concern” | Open Targets' class: business administrative | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-29Results posted on the registry: Yuan Yuan, Pembrolizumab + Olaparib (NCT03025035)
- 2025-05-13Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06966700)
- 2025-02-24Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06841354)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision